Literature DB >> 35305334

Research priorities to improve stroke outcomes.

Georgina Hill1, Sandra Regan1, Richard Francis2.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 35305334      PMCID: PMC8926410          DOI: 10.1016/S1474-4422(22)00044-8

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


× No keyword cloud information.
The James Lind Alliance (JLA) Stroke Priority Setting Partnership involved stroke survivors, carers, and health-care and other professionals in setting the research agenda by identifying and prioritising evidence uncertainties. Investment in research to address these uncertainties can ensure that more lives are saved and rebuilt after stroke. Research has identified several interventions that improve outcomes for patients after ischaemic stroke (eg, stroke unit care, thrombolysis, or thrombectomy). However, stroke remains a leading cause of death and disability worldwide. Although age-standardised stroke mortality has decreased, specific interventions for people with haemorrhagic stroke are needed. By 2035, in the UK, the incidence of stroke is expected to double compared with 2015. Even in people with mild disability or who make a complete physical recovery, fatigue and psychological issues can hugely affect quality of life. Further action is needed to improve interventions for primary and secondary stroke prevention, and rehabilitation to reduce the burden of stroke. However, only about 1·2% of research funding in the UK is spent on stroke, and the COVID-19 pandemic further reduced funding to this sector. Given the need for innovation in stroke care and restricted funds for research, the Stroke Priority Setting Partnership established a consensus on the priority areas to allocate resources that can have the greatest impact. In 2011, a JLA Partnership established research priorities on rehabilitation and long-term care, but priorities across the whole stroke pathway were still needed. We followed the well established JLA priority setting processes to ensure useful outcomes. In July, 2019, a steering group was set up that could represent people affected, health-care and other professionals, and third sector organisations in stroke. From February to August, 2020, more than 1400 stroke survivors, carers, and professionals participated in an online survey to collect unanswered questions for research. The submitted questions were checked against the partnership scope, existing evidence, and collated to form uncertainties. From February to March, 2021, stroke survivors, carers, and professionals participated in online surveys to prioritise uncertainties. In April, 2021, online workshops with stroke survivors, carers, and professionals reached a consensus on the top ten uncertainties. The Stroke Priority Setting Partnership generated two lists with ten uncertainties, ranked in order of importance, one for prevention and acute care and the other for rehabilitation and long-term care (table ; appendix pp 2–3). Six of the priority areas address stroke-related impairments. Three areas address stroke prevention, three focus on stroke treatment, and eight relate to delivery and experience of care. Psychological and cognitive effects remain top priorities since the previous JLA Partnership.
Table

Top priorities for stroke research

Prevention, diagnosis, and treatmentRehabilitation and long-term care
1Best interventions for primary stroke preventionAssessment of the impact of psychological effects and interventions to reduce them
2Recognition and early diagnosis of stroke and transient ischaemic attackEvaluation of cognitive disfunction and interventions to reduce it
3Evaluation of risks and benefits of intracerebral haemorrhage treatmentsAssessment of communication problems and interventions to reduce them
4New therapies for neuroprotectionUnderstanding fatigue and how to reduce it
5Risk of secondary stroke and secondary preventionOrganisation of community stroke services to meet all survivor needs
6Availability of thrombectomy to more patients with ischaemic strokeEvaluation of long-term effects on activities of daily living and interventions to tackle these effects
7Interventions to delay changes in brain function after subarachnoid haemorrhageEvaluation of the duration, intensity, location, and frequency of therapeutical interventions to achieve long-term outcomes
8Strategies to reduce complications of strokeImprovement of carers support
9Evaluation of risks and benefits, and personalised anticoagulation treatmentStrength and exercise interventions for recovery and secondary stroke prevention
10Effect of comorbidities and health characteristics on strokeImproving stroke survivor and carer experience of the stroke pathway
Top priorities for stroke research We provide a clear roadmap for research investment that can make the greatest impact to improve stroke outcomes. These priorities should inform the activities of funding bodies, researchers, and decision makers investing in stroke research. We declare no competing interests. Members of the Stroke Priority Setting Partnership Steering group are listed in the appendix (p 1).
  3 in total

1.  Top ten research priorities relating to life after stroke.

Authors:  Alex Pollock; Bridget St George; Mark Fenton; Lester Firkins
Journal:  Lancet Neurol       Date:  2012-03       Impact factor: 44.182

2.  Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

Authors: 
Journal:  Lancet Neurol       Date:  2019-03-11       Impact factor: 44.182

3.  The future incidence, prevalence and costs of stroke in the UK.

Authors:  Derek King; Raphael Wittenberg; Anita Patel; Zahid Quayyum; Vladislav Berdunov; Martin Knapp
Journal:  Age Ageing       Date:  2020-02-27       Impact factor: 10.668

  3 in total
  1 in total

1.  Exploring the perspectives of key stakeholders on the design and delivery of a cognitive rehabilitation intervention for people post-stroke.

Authors:  Mairéad O' Donoghue; Pauline Boland; Siobhan Leahy; Rose Galvin; John McManus; Dominika Lisiecka; Sara Hayes
Journal:  PLoS One       Date:  2022-06-16       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.